Showing results (91-100 of 218) with videos related to
Sort By:
Pageof 22
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.Nature Communications|January 10, 2018
Strain control of oxygen kinetics in the Ruddlesden-Popper oxide La1.85Sr0.15CuO4Tricia L Meyer, Ryan Jacobs, Dongkyu Lee, et al.Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.Clinical Lymphoma, Myeloma & Leukemia|December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosisJames Foran, Farhad Ravandi, William Wierda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinFarhad Ravandi, Eli Estey, Dan Jones, et al.Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.British Journal of Haematology|February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomesPreetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.Cancer|October 23, 2025
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lensHagop M Kantarjian, Gautam Borthakur, Naval Daver, et al.Pageof 22